IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 158 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (2,157 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures

 Article Access Statistics
    Viewed4285    
    Printed58    
    Emailed4    
    PDF Downloaded84    
    Comments [Add]    
    Cited by others 7    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2011  |  Volume : 77  |  Issue : 1  |  Page : 72-74

Treatment of severe nail psoriasis with etanercept


Department of Dermatology, Hospital dos Capuchos, Lisbon, Portugal

Date of Web Publication6-Jan-2011

Correspondence Address:
Joana Dias Coelho
Department of Dermatology, Hospital dos Capuchos, Alameda Santo António dos Capuchos, 1169-050 Lisbon
Portugal
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.74996

Get Permissions



How to cite this article:
Coelho JD, Diamantino F, Lestre S, Ferreira AM. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2011;77:72-4

How to cite this URL:
Coelho JD, Diamantino F, Lestre S, Ferreira AM. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol [serial online] 2011 [cited 2015 Sep 2];77:72-4. Available from: http://www.ijdvl.com/text.asp?2011/77/1/72/74996


Sir,

Nail involvement is common in psoriasis and has been reported to occur in up to 50% of patients. [1] It can cause significant physical impairment, severe distress and pain. [1],[2] There is a broad spectrum of nail dystrophies associated with psoriasis, ranging from the common pitting and loosening of the nail plate to the less frequent discoloration and splinter hemorrhages seen in the nail bed. [1] It is frequently refractory to treatment and there is no standardized therapy regimen. [3] Etanercept is a fully humanized, soluble tumor necrosis factor (TNF)-alpha receptor approved for the treatment of plaque psoriasis. It has been shown to be safe and to have long-term efficacy for treatment of moderate to severe psoriasis resistant to other modes. Some reports show that etanercept may have significant benefit in the treatment of psoriatic nail disease, although not approved for its treatment (as only manifestation). [1],[2],[3],[4]

We describe two cases of improvement of nail psoriasis with etanercept treatment. The severity of nail psoriasis was based on the Nail Psoriasis Severity Index (NAPSI). [5]

Case 1: A 59-year-old man with a 25-year history of plaque psoriasis, who after one episode of erythroderma and several systemic therapies (acitretin, methotrexate, cyclosporine), entered stabilization of the disease with Psoriasis Area Severity Index (PASI): 5 for the last 13 years. He was referred to our department because of severe nail psoriasis that was causing psychological distress. There was no improvement with topical application and intralesional injection of corticosteroids. All fingernails had psoriatic lesions (onycholysis, subungual hyperkeratosis, pitting and leukonychia) with NAPSI: 56. No symptoms of psoriatic arthritis were present. He was put on etanercept 50 mg twice a week (12 weeks), followed by etanercept 50 mg once a week (36 weeks), with NAPSI: 4 at week 48 (improvement of 92.9% of the nails' alterations) [Figure 1].
Figure 1 :(a– c) NAPSI: 56 at week 0 of treatment with etanercept; (d– g) NAPSI: 4 at week 48

Click here to view


Case 2:0 A 43-year-old man with a 15-year history of plaque psoriasis recalcitrant to traditional systemic therapies was put on efalizumab, with significant clinical improvement of cutaneous psoriasis. After 20 months of efalizumab administration, he had PASI:1 but maintained onycholysis, subungual hyperkeratosis and pitting of all fingers (NAPSI: 53). No symptoms of psoriatic arthritis were noted. We decided to switch from efalizumab to etanercept 50 mg twice a week. At week 12, he was placed on a regimen of etanercept 25 mg twice a week. A significant improvement in nail psoriasis was noted after 1 year of etanercept treatment, with NAPSI: 30 at week 48 (56.6% improvement of the nail psoriasis) [Figure 2].
Figure 2 :(a– c) NAPSI: 53 at week 0 of treatment with etanercept; (d– g) NAPSI: 30 at week 48

Click here to view


In both the patients, treatment was monitored closely. No side effects were present.

Recent studies have revealed that joint pain and nail psoriasis are responsible for impairment in quality of life. Etanercept therapy provided rapid improvement among patients with nail symptoms at baseline. [4]

In our two cases, the patients had been treated with several systemic therapies for psoriasis without improvement of nail manifestations. At week 48 of etanercept treatment, a good response was obtained with NAPSI improvement (92.9% and 56.6%, respectively). Both the patients were very much satisfied with the outcome.

 
  References Top

1.Jiaravuthisan M, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27.  Back to cited text no. 1
    
2.Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60-7.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Rallis E, Stavropoulou E, Rigopoulos D, Verros C. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008;35:544-5.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23:896-904.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  


    Figures

  [Figure 1], [Figure 2]

This article has been cited by
1 Evidence-Based Guidelines of the Spanish Psoriasis Group on the Use of Biologic Therapy in Patients With Psoriasis in Difficult-to-Treat Sites (Nails, Scalp, Palms, and Soles)
M. Sánchez-Regaña,M.J. Aldunce Soto,I. Belinchón Romero,M. Ribera Pibernat,R.F. Lafuente-Urrez,J.M. Carrascosa Carrillo,C. Ferrándiz Foraster,L. Puig Sanz,E. Daudén Tello,D. Vidal Sarró,R. Ruiz-Villaverde,E. Fonseca Capdevila,M.C. Rodríguez Cerdeira,M.M. Alsina Gibert,E. Herrera Acosta,S.E. Marrón Moya
Actas Dermo-Sifiliográficas (English Edition). 2014;
[Pubmed]
2 Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas)
M. Sánchez-Regaña,M.J. Aldunce Soto,I. Belinchón Romero,M. Ribera Pibernat,R.F. Lafuente-Urrez,J.M. Carrascosa Carrillo,C. Ferrándiz Foraster,L. Puig Sanz,E. Daudén Tello,D. Vidal Sarró,R. Ruiz-Villaverde,E. Fonseca Capdevila,M.C. Rodríguez Cerdeira,M.M. Alsina Gibert,E. Herrera Acosta,S.E. Marrón Moya
Actas Dermo-Sifiliográficas. 2014;
[Pubmed]
3 Psoriasis ungueal y su tratamiento con terapias biológicas
Ariel Hasson Nisis,Constanza del Puerto Troncoso,Cristián Navarrete-Dechent,Mario Pérez-Rivera
Piel. 2013; 28(3): 173
[Pubmed]
4 Biologic agents in nail psoriasis: efficacy data and considerations
Aikaterini Kyriakou,Aikaterini Patsatsi,Dimitrios Sotiriadis
Expert Opinion on Biological Therapy. 2013; 13(12): 1707
[Pubmed]
5 Treatment of Nail Psoriasis: Common Concepts and New Trends
Yasemin Oram,A. Deniz Akkaya
Dermatology Research and Practice. 2013; 2013: 1
[Pubmed]
6 Nail Psoriasis
Eugene S.T. Tan,Wei-Sheng Chong,Hong Liang Tey
American Journal of Clinical Dermatology. 2012; 13(6): 375
[Pubmed]
7 Etanercept in dermatological practice - Authorsæ own experience in the treatment of psoriasis vulgaris and psoriatic arthritis
Adamski, Z., Dudziak, M., Zakrzewska, K.
Postepy Dermatologii i Alergologii. 2011; 28(6): 435-441
[Pubmed]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow